A. Zati, D. Fortuna, A. Valent, M. V. Filippi, T. W. Bilotta
Laser in Medical Science, 2003
Background: low back pain with nerve root involvement is a very frequent symptom in patients affected by herniated intervertebral disk (1,2). In many cases symptoms resolve spontaneously in 12 mounths (4,5). For this reason conservative management is preferred to surgery (6). There are many methods of treatment but few, NSAIDs (12,13,14) TENS (transcutaneous electrical nerve stimulation) (15,16) have proven to be efficacious. Positive results regarding the employment of power laser in laser therapy (17,18,19,20,21,22) have led us to assess the efficacy of the laser in the treatment of this disease.
Objective: to compare the efficacy of Nd:YAG pulsed wave (pw) laser, TENS and NSAIDs in the symptomatic treatment of intervertebral disk displacement.
Materials and Methods: 60 patients with L4-L5 or L5-S1 intervertebral disk displacement affected by subacute back pain with nerve root involvement were divided into 3 groups. Each group underwent one of the following types of treatment for 15 days: NSAIDs (Ketoprofene), TENS or Nd:YAG laser. The assessment of the pain was carried out using two scales: Backill and VAS. Follow-up examinations were carried out 15 (T/1), 45 (T/2), and 180 (T/3) days from the beginning of treatment.
Results: at the end of the therapeutic cycle (T/l) all three methods were efficacious. Instead, at the subsequent follow-ups there was a different trend among laser treatment and the other methods. In fact, the positive effect of laser lasted into T/3 (180 days) while the score of patients treated by NSAIDs and TEN5 returned to initial values.
Conclusions: this trial highlights the superior results of laser therapy compared to those obtained by TENS and NSAIDs in the treatment of low back pain in patients affected by herniated intervertebral disk. The most striking results are represented by the longer duration of the laser effects. Despite its unclear biological effect, the High Power Laser Therapy (HILT) appears to be a interesting new treatment, worthy of further research.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.